Nancy Lamerigts

Background

About Nancy Lamerigts

From Medicine to MedTech Innovation: Building Companies That Move People If I hadn't been accepted into Medicine, I would have gone to the Academy of Industrial Design. That twist of fate shaped everything. My work ever since has balanced science and creativity, engineering and empathy, design and patient outcomes. My MedTech history started 1994. Before starting residency, I took a gap year that led to a PhD on bone graft incorporation. That project became my first true dive into medical engineering: designing studies, inventing implants, and learning the full cycle from concept to peer-reviewed publication. It revealed my love for R&D and the creative side of medicine: where ideas become tangible solutions. When the opportunity arose to co-found InSpine in 2005, I didn’t hesitate. What began as a small Dutch company has grown into an innovation platform that brought breakthroughs to spinal surgery. Together with visionary partners, I helped design and co-develop the first 3D-printed porous titanium spinal cages (EIT – Emerging Implant Technologies) in 2014. Later acquired by Johnson & Johnson MedTech in 2019. My current activities after 20+ years in MedTech are still related to InSpine. But I also co-founded and am a management team member of two breakthrough ventures: • Cresco Spine: Developing the SDS™, a disruptive growth-friendly implant for children with scoliosis • Atraxon Biotech: Tackling one of surgery's most painful problems: traumatic neuromas One thing I know: Medtech innovation rarely follows a straight line. The best ideas emerge where medicine, design, and human experience intersect. My unique edge is the combination of my medical background (MD, PhD in bone graft incorporation), my experience in successful orthopedic (start-up) companies and my proven track record from concept to acquisition. This experience is translated in my MedTech Value Engine: Providing insight in the viability and regulatory pathway of an idea or product, checking marketing maturity and translating science into signal by building product, company and founder stories, visibility and value. With the goal to become manifest to the KOL community, customers and investors and build value. Devices don’t change care because they are brilliant. They change care because someone makes their truth visible, safe, and obvious. Do you have a disruptive medical technology or idea but need the right strategy, network, and energy to take it further? Let’s connect and turn your concept into impact.